Management of Esophageal Candidiasis

First‑Line Oral Therapy

Oral fluconazole 200–400 mg (3–6 mg/kg) once daily for 14–21 days is the preferred initial systemic treatment, supported by strong evidence of efficacy. 1
A diagnostic therapeutic trial of fluconazole before endoscopy is cost‑effective in immunocompromised patients presenting with dysphagia or odynophagia. 1
Symptom improvement or resolution typically occurs within 7 days of starting fluconazole. 1

Intravenous fluconazole 400 mg (6 mg/kg) once daily is the preferred IV regimen. 1
Echinocandins can be used at higher doses than for candidemia:
- Micafungin 150 mg daily,
- Caspofungin 70 mg loading then 50 mg daily,
- Anidulafungin 200 mg daily.
Amphotericin B deoxycholate 0.3–0.7 mg/kg daily is a less preferred alternative. 1
Echinocandins, while achieving similar end‑of‑therapy efficacy, are associated with higher relapse rates and lower mycological cure rates compared with fluconazole; therefore they should not be first‑line when oral fluconazole is possible. 2
Patients who regain the ability to take oral medication should be de‑escalated to oral fluconazole 200–400 mg daily. 1

Itraconazole solution 200 mg daily for 14–21 days yields up to an 80 % response rate in fluconazole‑refractory cases. 1
Voriconazole 200 mg (≈3 mg/kg) twice daily (IV or oral) for 14–21 days is equally effective and suitable for refractory disease. 1
Alternative agents for refractory disease include:
- Echinocandins (same dosing as above) for 14–21 days,
- Amphotericin B deoxycholate 0.3–0.7 mg/kg daily for 21 days,
- Posaconazole (suspension 400 mg twice daily or extended‑release tablets 300 mg once daily) – evidence is weaker. 1

Fluconazole 100–200 mg three times weekly is recommended for long‑term suppression in patients with recurrent disease. 1
Suppressive therapy is especially important in patients with advanced AIDS, who are prone to repeated infections. 2

Initiation of antiretroviral therapy (ART) is strongly advised for all HIV‑infected patients to lower the risk of recurrent esophageal candidiasis. 1
Effective ART has markedly reduced the incidence and prevalence of esophageal candidiasis in the HIV population. 2
Esophageal candidiasis generally occurs at lower CD4‑cell counts than oropharyngeal candidiasis. 1

Candida albicans is the predominant pathogen; C. glabrata, C. dubliniensis, and C. krusei can also cause disease. 1
In immunocompromised hosts, the coexistence of oropharyngeal candidiasis with dysphagia or odynophagia is highly predictive of esophageal involvement. 1
However, esophageal candidiasis may present without concurrent oral thrush. 1

Do not select echinocandins as first‑line therapy when oral fluconazole is feasible, because of higher relapse rates. 2
Do not use candidemia‑dose echinocandin regimens for esophageal disease; higher doses are required to prevent relapse. 2
Do not postpone ART initiation in HIV‑infected patients; timely ART is the most effective long‑term strategy to prevent recurrence. 1

Fluconazole is superior to ketoconazole, itraconazole capsules, and flucytosine for treating esophageal candidiasis. 1
Voriconazole demonstrates efficacy comparable to fluconazole and is effective for fluconazole‑refractory infections. 1